IN-1233, an ALK-5 inhibitor: prevention of granulation tissue formation after bare metallic stent placement in a rat urethral model.

Abstract

PURPOSE:

To evaluate the efficacy of an activin receptor-like kinase-5 inhibitor, IN-1233, for the prevention of tissue hyperplasia after bare stent placement in a rat urethral model.

MATERIALS AND METHODS:

Procedures were performed in accordance with the National Institutes of Health guidelines for humane handling of animals; approval of the committee of animal research was obtained. In 20 Sprague-Dawley male rats (weight range, 300-350 g), a self-expanding metallic bare stent was inserted in the urethra by using fluoroscopic guidance. One group of 10 rats (group A) was treated with IN-1233, the other group of 10 rats (group B) received no treatment. Retrograde urethrography was performed 4 and 8 weeks after stent placement. All rats were sacrificed at 8 weeks for histologic analysis.

RESULTS:

Stent placement was technically successful in all rats. The average stent diameter was significantly larger in group A compared with group B at follow-up retrograde urethrography performed 4 (P = .006) and 8 (P < .001) weeks after stent placement. At histologic analysis, the percentage of granulation tissue area (P < .001), thickness of submucosal fibrosis (P < .001), and number of epithelial layers (P < .001) were significantly decreased in group A compared with group B. Inflammatory cell infiltration (P < .001) was significantly increased in group A compared with group B.

CONCLUSION:

IN-1233 is effective for the prevention of granulation tissue formation after bare metallic stent placement in a rat urethral model.

• Authors: Jin Hyoung Kim, Ho-Young Song, Jung-Hoon Park, Hyun-Jung Yoon, Hyung Gyu Park, Dae-Kee Kim
• Journal: Radiology (Radiology) Vol. 255 Issue 1 Pg. 75-82 (Apr 2010) ISSN: 1527-1315 [Electronic] United States
• PMID: 20308445 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: RSNA, 2010

Chemical References

• 3-((4-(6-methylpyridin-2-yl)-5-(quinolin-6-yl)-1H-imidazol-2-yl)methyl)benzamide
• Benzamides
• Metals
• Quinolines

Topics

• Animals
• Benzamides (pharmacology)
• Granulation Tissue (diagnostic imaging, drug effects, pathology)
• Hyperplasia
• Male
• Metals
• Quinolines (pharmacology)
• Radiography
• Rats
• Rats, Sprague-Dawley
• Statistics, Nonparametric
• Stents (adverse effects)
• Urethra (diagnostic imaging, drug effects, pathology)